Current understanding and future directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice

What is it about?

As a novel biomarker for predicting AKI, [TIMP-2]•[IGFBP7] has already proved its validity and accuracy in multiple studies in many fields and has been applied by the FDA for clinical application. Further studies regarding the application value of [TIMP-2]•[IGFBP7] in different clinical contexts, different patient populations, different disease spectrum, are needed.

Featured Image